Nanogen Pharmaceutical Biotechnology
Seoul, South Korea· Est.
South Korean biotech leveraging nanobody‑based therapeutics for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
South Korean biotech leveraging nanobody‑based therapeutics for oncology and immunology.
OncologyImmunology
Technology Platform
Proprietary nanobody platform generating ultra‑small, high‑affinity single‑domain antibodies for targeted therapy and payload delivery.
Opportunities
Successful IND filings could unlock substantial Series B financing and strategic partnerships, leveraging the growing demand for antibody‑fragment therapeutics.
Risk Factors
Funding dilution, regulatory uncertainties, and the challenge of translating pre‑clinical efficacy to human trials pose significant risks.
Competitive Landscape
Nanogen’s nanobody format offers superior tissue penetration and modularity compared with traditional monoclonal antibodies, differentiating it from larger antibody developers.